398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648

[6] Department of Oncology and Radiotherapy, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, Poland

[NORA names: Poland; Europe, EU; OECD];

[7] Department of Surgery, Japanese Red Cross Akita Hospital, Akita, Japan

[NORA names: Japan; Asia, East; OECD];

[8] Kanagawa Prefectural Hospital Organization

[NORA names: Japan; Asia, East; OECD];

[9] Kindai University

[NORA names: Japan; Asia, East; OECD];

[10] National Taiwan University Hospital

[NORA names: Taiwan; Asia, East];

[11] Centre Oscar Lambret

[NORA names: France; Europe, EU; OECD];

[12] Fondazione IRCCS Istituto Nazionale dei Tumori

[NORA names: Italy; Europe, EU; OECD];

[13] Universidade de São Paulo

[NORA names: Brazil; America, South];

[14] Odense University Hospital

[NORA names: Region of Southern Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];

[15] Bristol-Myers Squibb (United States)

[NORA names: United States; America, North; OECD];

[16] Ono Pharmaceutical (Japan)

[NORA names: Japan; Asia, East; OECD];

[17] National Cancer Centre Japan

[NORA names: Japan; Asia, East; OECD];

[18] Osaka University

[NORA names: Japan; Asia, East; OECD]

(less)